Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors

Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2:1–17. doi:10.2174/1568011023354290

Bacher G, Nickel B, Emig P et al (2001) D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 61:392–399

Baxter (2005) Investigator’s brochure indibulin

Hussain M, Wozniak AJ, Edelstein MB (1993) Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol 14:61–75. doi:10.1016/1040-8428(93)90006-P

Hilkens PH, Verweij J, Vecht CJ et al (1997) Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 8:187–190. doi:10.1023/A:1008245400251

Freilich RJ, Balmaceda C, Seidman AD et al (1996) Motor neuropathy due to docetaxel and paclitaxel. Neurology 47:115–118

Windebank AJ (1999) Chemotherapeutic neuropathy. Curr Opin Neurol 12:565–571. doi:10.1097/00019052-199910000-00010

Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48:353–374. doi:10.1146/annurev.med.48.1.353

Schiller JH (1998) Role of taxanes in lung-cancer chemotherapy. Cancer Invest 16:471–477. doi:10.3109/07357909809011701

Kuppens IE, Witteveen PO, Schot M et al (2007) Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors. Invest New Drugs 25:227–235. doi:10.1007/s10637-006-9027-2

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216. doi:10.1093/jnci/92.3.205

Stokvis E, Nan-Offeringa LG, Ouwehand M et al (2004) Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 18:1465–1471. doi:10.1002/rcm.1493

Veltkamp SA, Rosing H, Huitema AD et al (2007) Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. Cancer Chemother Pharmacol 60:635–642. doi:10.1007/s00280-006-0405-4

Veltkamp SA, Alderden-Los C, Sharma A et al (2007) A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. Cancer Chemother Pharmacol 59:43–50. doi:10.1007/s00280-006-0245-2

Veltkamp SA, Thijssen B, Garrigue JS et al (2006) A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 95:729–734. doi:10.1038/sj.bjc.6603312